Correlation between RASSF1A Methylation in Cell-Free DNA and the Prognosis of Cancer Patients: A Systematic Review and Meta-Analysis

Table 1

Details of the nine included studies.

Study	Country	Study type	Patients	Timing sample	, M/F	Age, years	Methylation, Y/N	Follow-up, months	Outcomes
Balgkouranidouet al. [13]	Greece	NR	GC	Preoperatively	73, 51/22		50/23	56 (12–111)^$	OS
Fiegl et al. [14]	Austria	PCS	BC	Pretherapeutic	148, 0/148	62 (37–88)^$	29/119	48 (6–117)^$	OS, RFS
Gӧbel et al. [17]	Austria	PCS	BC	During surgery	357, 0/357	57.4 (50.0, 66.3)^#	78/279	51 (35, 68)^#	OS, DFS
Karamitrousis et al. [16]	Greece	NR	GC	Pre-therapeutic	70, 43/27		52/18	Up to 48	OS, PFS
Matthaios et al. [15]	Greece	NR	eCRC	Preoperatively	88, 51/37	70 (44–76)^$	22/66	Up to 111	OS
			mCRC	Pretherapeutic	67, 38/29	70 (44–76)^$	30/37	Up to 67	OS
Pimson et al. [23]	Thailand	NR	GC	Pretherapeutic	101, 44/57	41–50/29 51–60/	84/17	Up to 120	OS
Rasmussen et al. [24]	Denmark	RCS	CRC	Pretherapeutic	193, 119/74		22/171	Up to 60	OS
Saliminejad et al. [25]	Iran	NR	GC	Pretherapeutic	96, 62/34		32/64	Median 20	OS
Zavridou et al. [26]	Greece	PCS	mCRPC	Pretherapeutic	61, 61/0	NR	14/47	Up to 60	OS

PCS: prospective cohort study; RCS: retrospective cohort study; NR: not reported; BC: breast cancer; CRC: colorectal cancer; eCRC: early operable colorectal cancer; mCRC: metastatic colorectal cancer; mCRPC: metastatic castration-resistant prostate cancer; GC: gastric cancer; M: male; F: female; Y: yes; N: no; OS: overall survival; RFS: relapse-free survival; DFS: disease-free survival; PFS: progression-free survival. ^$Median (range); ^#Median (interquartile range).